Genetic and molecular targets in lymphoma: Implications for prognosis and treatment

Future Oncology

Volumn 10, Issue 15, 2014, Pages 2509-2528

  Bachegowda, Lohith S ^a,b   Barta, Stefan K ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

BCL 6; chemokines; ibrutinib; immunomodulatory drugs; ipilimumab; JAK STAT pathway inhibitors; NF B; PD 1

Indexed keywords

B LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; IPILIMUMAB; JANUS KINASE; JANUS KINASE 2 INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN CCND1; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C INHIBITOR; STAT PROTEIN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE REGULATION; CELL MOTILITY; EPIGENETICS; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOREGULATION; LYMPHOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

EID: 84919969356     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.112     Document Type: Review

References (178)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. 16(8), 2780-2795 (1998).
2. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. http://seer.cancer.gov
3. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333(23), 1540-1545 (1995).
4. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359(6), 613-626 (2008).
5. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000).
6. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67(3), 333-350 (2007).
7. Thieblemont C, Briere J. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? Blood 121(12), 2165-2166 (2013).
8. Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood 117(8), 2319-2331 (2011).
9. Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk. Lymphoma 42(5), 1089-1098 (2001).
10. Juszczynski P, Chen L, O'Donnell E et al. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 114(26), 5315-5321 (2009).
11. Parekh S, Polo JM, Shaknovich R et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 110(6), 2067-2074 (2007).
12. Ranuncolo SM, Polo JM, Dierov J et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8(7), 705-714 (2007).
13. Wagner SD, Ahearne M, Ko Ferrigno P. The role of BCL6 in lymphomas and routes to therapy. Br. J. Haematol. 152(1), 3-12 (2011).
14. Bilalovic N, Blystad AK, Golouh R et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am. J. Clin. Pathol. 121(1), 34-42 (2004).
15. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11), 4207-4213 (2006).
16. Offit K, Lo Coco F, Louie DC et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N. Engl. J. Med. 331(2), 74-80 (1994).
17. Shustik J, Han G, Farinha P et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 95(1), 96-101 (2010).
18. Wilson WH, Jung SH, Porcu P et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5), 758-765 (2012).
19. Parekh S, Prive G, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leuk. Lymphoma 49(5), 874-882 (2008).
20. Cerchietti LC, Ghetu AF, Zhu X et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17(4), 400-411 (2010).
21. Briones J. Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition. Expert Rev. Hematol. 3(2), 157-159 (2010).
22. Ci W, Polo JM, Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr. Opin. Hematol. 15(4), 381-390 (2008).
23. Griffiths GJ, Dubrez L, Morgan CP et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 144(5), 903-914 (1999).
24. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87(1), 265-272 (1996).
25. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 100(12), 3935-3941 (2002).
26. Lopez-Guillermo A, Cabanillas F, Mcdonnell TI et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93(9), 3081-3087 (1999).
27. Iqbal J, Meyer PN, Smith LM et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin. Cancer Res. 17(24), 7785-7795 (2011).
28. Pro B, Leber B, Smith M et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br. J. Haematol. 143(3), 355-360 (2008).
29. Seymour JF, Davids MS, Pagel JM et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma. Presented at: American Society of Hematology Meeting. New Orleans, LA, USA, 7-10 December 2013 (Abstract 872).
30. Davids MS, Seymour JF, Gerecitano JF et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/ refractory (r/r) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Presented at: American Society of Hematology Meeting. New Orleans, LA, USA, 7-10 December 2013 (Abstract 1789).
31. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol. Pathol. 51(1), 1-7 (1998).
32. Yatabe Y, Suzuki R, Tobinai K et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95(7), 2253-2261 (2000).
33. Klier M, Anastasov N, Hermann A et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22(11), 2097-2105 (2008).
34. Bonvini P, Zorzi E, Mussolin L et al. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica 94(7), 944-955 (2009).
35. Lin TS, Blum KA, Fischer DB et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J. Clin. Oncol. 28(3), 418-423 (2010).
36. Kouroukis CT, Belch A, Crump M et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(9), 1740-1745 (2003).
37. Lin TS, Ruppert AS, Johnson AJ et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 27(35), 6012-6018 (2009).
38. Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in human cancer. J. Cell. Mol. Med. 6(2), 151-159 (2002).
39. Friedberg JW. Double-hit diffuse large B-cell lymphoma. J. Clin. Oncol. 30(28), 3439-3443 (2012).
40. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17), 3533-3537 (2009).
41. Hartmann E, Fernandez V, Moreno V et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J. Clin. Oncol. 26(30), 4966-4972 (2008).
42. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30(28), 3452-3459 (2012).
43. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30(28), 3460-3467 (2012).
44. Jain M, Arvanitis C, Chu K et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297(5578), 102-104 (2002).
45. Leonetti C, Biroccio A, Benassi B et al. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. 8(6), 459-468 (2001).
46. Hermeking H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 3(3), 163-175 (2003).
47. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011).
48. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. Educ. Program 331-349 (2003).
49. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk. Lymphoma 49(7), 1238-1245 (2008).
50. Martiniani R, Di Loreto V, Di Sano C, Lombardo A, Liberati AM. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv. Hematol. 842945, 2012 (2012).
51. Yang Y, Shaffer AL 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6), 723-737 (2012).
52. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 26(30), 4952-4957 (2008).
53. Boll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br. J. Haematol. 148(3), 480-482 (2010).
54. Wiernik PH. Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opin. Pharmacother. 14(4), 475-488 (2013).
55. Sher T, Miller KC, Lawrence D et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymphoma 51(1), 85-88 (2010).
56. Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J. Clin. Oncol. 31(29), 3688-3695 (2013).
57. Chiappella A, Silvia Franceschetti, Alessia Castellino et al. Final results of Phase II study of lenalidomide plus rituximab-chop21 in elderly untreated diffuse large b-cell lymphoma focusing on the analysis of cell of origin: real07 trial of the fondazione italiana linfomi. Presented at: American Society of Hematology Meeting. New Orleans, LA, USA, 7-10 December 2013 (Abstract Oral Session 850).).
58. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29(6), 313-326 (2009).
59. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 256(2), 137-165 (2007).
60. Takahashi K. Serum CCL3 and CCL4 levels function as novel prognostic markers in diffuse large B cell lymphoma. ASH 120(21), 2627 (2012).
61. Hussain SK, Hessol NA, Levine AM et al. Serum biomarkers of immune activation and subsequent risk of non-Hodgkin B-cell lymphoma among HIV-infected women. Cancer Epidemiol. Biomarkers Prev. 22(11), 2084-2093 (2013).
62. Crazzolara R, Johrer K, Johnstone RW et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol. 119(4), 965-969 (2002).
63. De Rooij MF, Kuil A, Geest CR et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11), 2590-2594 (2012).
64. Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(9), 1591-1598 (2010).
65. Ogura M, Ishida T, Hatake K et al. Multicenter Phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-Cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 32(11), 1157-1163 (2014).
66. Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J. Biol. Med. 84(4), 409-421 (2011).
67. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/ medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am. J. Surg. Pathol. 36(1), 109-116 (2012).
68. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17), 3268-3277 (2010).
69. Carreras J, Lopez-Guillermo A, Roncador G et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 27(9), 1470-1476 (2009).
70. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum. Pathol. 42(4), 552-557 (2011).
71. Chu F, Ma W, Yamazaki T et al. PD-1+ T cell subsets in follicular lymphoma tumor microenvironment and their implications for prognosis and therapy. American Society of Hematology Meeting. San Diego, CA, USA, 11 December 2011 (Abstract 2648).).
72. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
73. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 17(13), 4232-4244 (2011).
74. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
75. Westin JR, Chu F, Fayad L. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 10 December 2012 (Abstract 793).
76. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19(13), 3462-3473 (2013).
77. Liapis K, Clear A, Owen A et al. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 122(3), 424-433 (2013).
78. Charles A Janeway Jr, Paul Travers, Mark Walport, Mark J Shlomchik. Immunobiology: the Immune System in Health and Disease (5th Edition). Garland Science, NY, USA (2001).
79. Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 229(1), 337-355 (2009).
80. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother. Radiopharm. 25(6), 601-613 (2010).
81. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
82. Ansell SM, Hurvitz SA, Koenig PA et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15(20), 6446-6453 (2009).
83. Bashey A, Medina B Corringham S et al. CTLA-4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoeitic stem cell transplantation. Blood 113, 1581-1588 (2009).
84. Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma. Curr. Opin. Hematol. 18(4), 293-299 (2011).
85. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther. 10(6), 935-954 (2010).
86. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007).
87. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
88. Younes A, Oki Y, Bociek RG et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, Phase 2 trial. Lancet Oncol. 12(13), 1222-1228 (2011).
89. Younes A, Sureda A, Ben-Yehuda D et al. Panobinostat in patients with relapsed/ refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a Phase II study. J. Clin. Oncol. 30(18), 2197-2203 (2012).
90. Sahakian E, Rock-Klotz J, Shah B et al. Combination of ACY1215, a selective histone deacetylase 6 (HDAC6) inhibitor with the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, represents a novel therapeutic strategy in mantle cell lymphoma (MCL). Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 1660).
91. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 20(8), 1293-1302 (2009).
92. De S, Shaknovich R, Riester M et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 9(1), e1003137 (2013).
93. Velichutina I, Shaknovich R, Geng H et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116(24), 5247-5255 (2010).
94. Elstrom RL, Cerchietti L, Martin P et al. Azacitidine priming prior to R-CHOP is feasible and results in global demethylation, restoration of TGF-beta pathway, and improved chemotherapy sensitivity in patients with newly diagnosed DLBCL. American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 3706).
95. Clozel T, Yang S, Elstrom RL et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 3(9), 1002-1019 (2013).
96. Blum KA, Liu Z, Lucas DM et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br. J. Haematol. 150(2), 189-195 (2010).
97. Bachegowda L, Gligich O, Mantzaris I et al. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J. Hematol. Oncol. 6, 50 (2013).
98. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007), 461-466 (2004).
99. Ersing I, Bernhardt K, Gewurz BE. NF-kappaB and IRF7 pathway activation by Epstein-Barr virus latent membrane protein 1. Viruses 5(6), 1587-1606 (2013).
100. Swanson-Mungerson M, Bultema R, Longnecker R. Epstein-Barr virus LMP2A imposes sensitivity to apoptosis. J. Gen. Virol. 91(Pt 9), 2197-2202 (2010).
101. Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247), 717-721 (2009).
102. Juvekar A, Manna S, Ramaswami S et al. Bortezomib induces nuclear translocation of IkappaBalpha resulting in gene-specific suppression of NF-kappaB-dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9(2), 183-194 (2011).
103. Goy A, Younes A, Mclaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23(4), 667-675 (2005).
104. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24(30), 4867-4874 (2006).
105. Di Bella N, Taetle R, Kolibaba K et al. Results of a Phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 115(3), 475-480 (2010).
106. O'connor OA, Portlock C, Moskowitz C et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin. Cancer Res. 16(2), 719-726 (2010).
107. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29(6), 690-697 (2011).
108. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a Phase 2 study of the European Myeloma Network (EMN). Blood 122(19), 3276-3282 (2013).
109. Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(27), 4293-4297 (2007).
110. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36(6), 320-328 (2011).
111. Xu ZZ, Xia ZG, Wang AH et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann. Hematol. 92(10), 1351-1358 (2013).
112. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11(5), 329-341 (2010).
113. Furman RR, Flinn IW, Coutre SE et al. Interim results from a Phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J. Clin. Oncol. 28(15s Suppl.), Abstract 3032 (2010).
114. Finn. A Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies J. Clin. Oncol. 29(Suppl.), Abstract 6631 (2011).
115. Gopal AK, Kahl BS, De Vos S et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370(11), 1008-1018 (2014).
116. Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370(11), 997-1007 (2014).
117. Horwitz S, Finn I, Patel M et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase in patients with relapsed/refractory lymphoma. Presented at: American Society of Clinical Oncology 2013 Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 8518).).
118. Steven M. Horwitz IF, Patel MR, Younes A. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase in patients with relapsed/ refractory lymphoma. ASCO supplement. http://meetinglibrary.asco.org
119. Hong JY, Choi MK, Kim YS et al. The impact of activated akt expression on clinical outcome in diffuse large B-cell lymphoma: a clinicopathological study of 99 cases. Presented at: American Society of Hematology 2012 Meeting.Atlanta, GA, USA, 8-11 December 2012 (Abstract 2676).
120. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 113(8), 1723-1729 (2009).
121. Petrich AM, Leshchenko V, Kuo PY et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin. Cancer Res. 18(9), 2534-2544 (2012).
122. Guidetti A, Viviani S, Marchiano A et al. Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: final results of a Phase II trial. Presented at: American Society of Hematology 2012 Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 3679).
123. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23(23), 5347-5356 (2005).
124. Ansell SM, Inwards DJ, Rowland KM Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3), 508-514 (2008).
125. Smith SM, Van Besien K, Karrison T et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II consortium. J. Clin. Oncol. 28(31), 4740-4746 (2010).
126. Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a Phase 2 study. Lancet Oncol. 12(4), 361-368 (2011).
127. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27(23), 3822-3829 (2009).
128. Witzig TE, Reeder CB, Laplant BR et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25(2), 341-347 (2011).
129. Ghobrial IM, Gertz M, Laplant B et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J. Clin. Oncol. 28(8), 1408-1414 (2010).
130. Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin. Investig. Drugs 22(6), 775-785 (2013).
131. Kleppe M, Tousseyn T, Geissinger E et al. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma. Haematologica 96(11), 1723-1727 (2011).
132. Ding BB, Yu JJ, Yu RY et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3), 1515-1523 (2008).
133. Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110(9), 3387-3390 (2007).
134. Zamo A, Chiarle R, Piva R et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21(7), 1038-1047 (2002).
135. Rui L, Emre NC, Kruhlak MJ et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18(6), 590-605 (2010).
136. Rui, L. The JAK-STAT pathway and hematological malignancy: beyond stats. J. Hematol. Transfus. 1(1), 1002 (2013).
137. Twa DD, Chan FC, Ben-Neriah S et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123(13), 2062-2065 (2014).
138. Butterbach K, Beckmann L, De Sanjose S et al. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph). Br. J. Haematol. 153(3), 318-333 (2011).
139. Martini M, Hohaus S, Petrucci G et al. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. Am. J. Clin. Pathol. 129(3), 472-477 (2008).
140. Wu ZL, Song YQ, Shi YF, Zhu J. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J. Hematol. Oncol. 4(1), 31 (2011).
141. Huang X, Meng B, Iqbal J et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. (2013).
142. Chiarle R, Simmons WJ, Cai H et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11(6), 623-629 (2005).
143. Baus D, Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. J. Int. Cancer 118(6), 1404-1413 (2006).
144. Kirk R. Haematological cancer: hit the lymphoma, JAK. Nat. Rev. Clin. Oncol. 9(11), 608 (2012).
145. Coffey G, DeGuzzman F, Lee G et al. PRT062070: a dual Syk/JAK inhibitor with potent immune regulatory capacity in rodent models of inflammation and cancer. Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 2764).
146. Younes A, Romaguera J, Fanale M et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30(33), 4161-4167 (2012).
147. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J. Clin. Oncol. 31(1), 128-130 (2013).
148. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discovery 12(3), 229-243 (2013).
149. Byrd JC. Therapeutic targeting of B-cell receptor signaling pathways. Presented at: American Society Of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 27).
150. Pogue SL, Kurosaki T, Bolen J, Herbst R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J. Immunol. 165(3), 1300-1306 (2000).
151. Young RM, Hardy IR, Clarke RL et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 113(11), 2508-2516 (2009).
152. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
153. Feldman AL, Sun DX, Law ME et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 22(6), 1139-1143 (2008).
154. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88-94 (2013).
155. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. (2013).
156. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32-42 (2013).
157. Wilson W, Gerecitano J, Goy A et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/ refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, Phase 2 study. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 686).).
158. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat. Immunol. 5(8), 785-790 (2004).
159. Li S, Phong M, Lahn M et al. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol. Direct 2, 8 (2007).
160. Hans CP, Weisenburger DD, Greiner TC et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. 18(10), 1377-1384 (2005).
161. Riihijarvi S, Koivula S, Nyman H, Rydstrom K, Jerkeman M, Leppa S. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod. Pathol. 23(5), 686-693 (2010).
162. Naylor TL, Tang H, Ratsch BA et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 71(7), 2643-2653 (2011).
163. Morschhauser F, Seymour JF, Kluin-Nelemans HC et al. A Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. 19(2), 247-253 (2008).
164. Schwartzberg L, Hermann R, Finn I et al. Phase II study of enzastaurin in patients with follicular lymphoma: updated final clinical results and immunohistochemical correlations. Presented at: American Society of Hematology Meeting. Atlanta, GA, USA 8-11 December 2012 (Abstract 777).).
165. Crump M, Leppa S, Fayad L et al. A Phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial. Presented at: American Society of Hematology. New Orleans, LA, USA 7-10 December 2013 (Abstract 371).
166. Leonard JP, Lacasce AS, Smith MR et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119(20), 4597-4607 (2012).
167. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 31(33), 4199-4206 (2013).
168. Kirschbaum MH, Goldman BH, Zain JM et al. A Phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk. Lymphoma 53(2), 259-262 (2012).
169. Hofmeister C, Bowers M, Baiocchi R et al. Post autologous transplant vorinostat (SAHA) in high risk lymphoma: Phase 1 study of vorinostat maintenance. American Society of Hematology 2012 Meeting. Atlanta, GA, USA, 8-11 December 2012 (Abstract 2004). ).
170. Vb T. A Phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation Blood 122(21), (2013).
171. Pohlman B. Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Presented at: ASH Annual Meeting.New Orleans, LA, USA, 6-9 December 2009.
172. Stathis A, Hotte SJ, Chen EX et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin. Cancer Res. 17(6), 1582-1590 (2011).
173. Hainsworth JM, Arrowsmith E, McCleoid M. Randomized Phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate-and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. Presented at: American Society of Clinical Oncology Meeting. Chicago, IL, USA, 3-7 June 2011 (Abstract 8016).
174. Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod. Pathol. 23(7), 909-920 (2010).
175. Kramer MH, Hermans J, Parker J et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J. Clin. Oncol. 14(7), 2131-2138 (1996).
176. Klapper W, Stoecklein H, Zeynalova S et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 22(12), 2226-2229 (2008).
177. Bavi P, Uddin S, Bu R et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J. Pathol. 224(3), 355-366 (2011).
178. Hasselblom S, Hansson U, Olsson M et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br. J. Haematol. 149(4), 560-568 (2010).